These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [Cancer treatment--is there progress?]. Heinzl S Med Monatsschr Pharm; 1996 Mar; 19(3):65. PubMed ID: 8868962 [No Abstract] [Full Text] [Related]
4. Drop-out rates of cancer patients participating in longitudinal RCTs. Mathibe LJ Contemp Clin Trials; 2007 Jul; 28(4):340-2. PubMed ID: 17449332 [No Abstract] [Full Text] [Related]
5. Examining heterogeneity in phase II trial designs may improve success in phase III. Tuma RS J Natl Cancer Inst; 2008 Feb; 100(3):164-6. PubMed ID: 18230788 [No Abstract] [Full Text] [Related]
6. Early average change in tumor size in a phase 2 trial: efficient endpoint or false promise? Rubinstein LV; Dancey JE; Korn EL; Smith MA; Wright JJ J Natl Cancer Inst; 2007 Oct; 99(19):1422-3. PubMed ID: 17895470 [No Abstract] [Full Text] [Related]
7. The sword of Damocles and the treatment of stage I seminoma. Oliver T; Mead G; Mason M; Stenning S; Dieckmann K; Steiner H; De Santis M; Aparicio J; Skoneczna I; Kratzik C J Clin Oncol; 2006 Jun; 24(16):2599-600. PubMed ID: 16735720 [No Abstract] [Full Text] [Related]
8. Criticism of tumor response criteria raises trial design questions. Twombly R J Natl Cancer Inst; 2006 Feb; 98(4):232-4. PubMed ID: 16478740 [No Abstract] [Full Text] [Related]
9. The lingo of chemo. How language misleads patients with cancer. Napoli M Am J Nurs; 2000 Apr; 100(4):13. PubMed ID: 10776339 [No Abstract] [Full Text] [Related]
10. Treatment of recurrent small cell lung cancer. Davies AM; Evans WK; Mackay JA; Shepherd FA Hematol Oncol Clin North Am; 2004 Apr; 18(2):387-416. PubMed ID: 15094178 [No Abstract] [Full Text] [Related]
11. Phase II trials in journal of clinical oncology. Cannistra SA J Clin Oncol; 2009 Jul; 27(19):3073-6. PubMed ID: 19451415 [No Abstract] [Full Text] [Related]
12. Complementary and alternative medicine among advanced cancer patients enrolled on phase I trials: a study of prognosis, quality of life, and preferences for decision making. Hlubocky FJ; Ratain MJ; Wen M; Daugherty CK J Clin Oncol; 2007 Feb; 25(5):548-54. PubMed ID: 17290064 [TBL] [Abstract][Full Text] [Related]
13. The case for neoadjuvant chemotherapy and cystectomy for muscle invasive bladder cancer. deVere White RW; Katz MH; Steinberg GD J Urol; 2009 May; 181(5):1994-7. PubMed ID: 19286209 [No Abstract] [Full Text] [Related]
14. [Current approaches in prevention and therapy of chemo- and radiotherapy-induced oral mucositis]. Rosenthal C; Karthaus M Wien Med Wochenschr; 2001; 151(3-4):53-65. PubMed ID: 11789420 [TBL] [Abstract][Full Text] [Related]
15. Development of growth inhibitory agents in urological and other malignancies. Stadler WM BJU Int; 2006 Sep; 98(3):497-502. PubMed ID: 16827906 [No Abstract] [Full Text] [Related]
16. Evaluation of randomized discontinuation design. Freidlin B; Simon R J Clin Oncol; 2005 Aug; 23(22):5094-8. PubMed ID: 15983399 [TBL] [Abstract][Full Text] [Related]
18. [Off-label prescriptions. Drug use outside of established guidelines and treatment standard]. Weissbach L; Boedefeld EA Urologe A; 2003 Mar; 42(3):428-32. PubMed ID: 12723544 [No Abstract] [Full Text] [Related]
19. Trend toward noninferiority trials may mean more difficult interpretation of trial results. Tuma RS J Natl Cancer Inst; 2007 Dec; 99(23):1746-8. PubMed ID: 18042926 [No Abstract] [Full Text] [Related]
20. [Bortezomib in second-line therapy]. Musch A Med Monatsschr Pharm; 2005 Sep; 28(9):332-3. PubMed ID: 16163891 [No Abstract] [Full Text] [Related] [Next] [New Search]